title: Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases.
abstract: OBJECTIVE
  The current usage of hormone therapy (HT) among perimenopausal women is low in China, especial in women with premature ovarian insufficiency (POI) with malignant hematologic diseases. This study investigated the efficacy and safety of HT in POI patients with malignant hematologic diseases who have received myeloablative chemotherapy and hemopoietic stem cell transplantation (HSCT).
  
  
  METHODS
  Patients who had POI after myeloablative chemotherapy and HSCT for malignant hematologic diseases were enrolled. Questionnaires with information about characteristics, menstrual status, sex hormone levels and menopausal symptoms were used to evaluate the relief from menopausal symptoms and safety of HT.
  
  
  RESULTS
  Among 130 cases, 103 (79.2%) patients had perimenopausal symptoms. The mean total Kupperman menopausal index score changed significantly from 13.50 ± 7.128 to 6.13 ± 5.97 after HT for 24 months. Among the 118 patients who received estrogen/progestin cyclic sequential therapy, 89 (75.4%) had withdrawal bleeding.
  
  
  CONCLUSIONS
  Myeloablative chemotherapy against leukemia may cause POI. HT may relieve perimenopausal symptoms after myeloablative chemotherapy and HSCT. HT was safe and no excessive recurrences or mortality were seen in the hormone-treated group for patients who survived from malignant hematologic diseases and who received HSCT.
authors.affiliation: a Department of Obstetrics and Gynecology , Peking University People's Hospital , Beijing , China.
authors.forename: X
authors.initials: X
authors.lastname: Yang
authors.affiliation: a Department of Obstetrics and Gynecology , Peking University People's Hospital , Beijing , China.
authors.forename: C
authors.initials: C
authors.lastname: Wang
authors.affiliation: b Department of Obstetrics and Gynecology , The Second Hospital of Hebei Medical University , Shijiazhuang , Hebei Province , China.
authors.forename: X
authors.initials: X
authors.lastname: He
authors.affiliation: b Department of Obstetrics and Gynecology , The Second Hospital of Hebei Medical University , Shijiazhuang , Hebei Province , China.
authors.forename: J
authors.initials: J
authors.lastname: Wei
authors.affiliation: c Department of Obstetrics and Gynecology , Peking University Third Hospital , Beijing , China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.affiliation: b Department of Obstetrics and Gynecology , The Second Hospital of Hebei Medical University , Shijiazhuang , Hebei Province , China.
authors.forename: X
authors.initials: X
authors.lastname: Li
authors.affiliation: d Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Peking University Institute of Hematology, People's Hospital , Beijing , China.
authors.forename: L-P
authors.initials: LP
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D002681:China; D015914:Estrogen Replacement Therapy; D005260:Female; D006402:Hematologic Diseases; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016649:Primary Ovarian Insufficiency / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
keywords: Premature ovarian failure; hemopoietic stem cell transplantation; hormone therapy; leukemia; myeloablative chemotherapy